LncRNAs: Emerging biomarkers in gastric cancer

Future Oncology

Volumn 11, Issue 17, 2015, Pages 2427-2441

  Gu, Yu ^a,b   Chen, Tianxiang ^c   Li, Guangliang ^d   Yu, Xiongfei ^a   Lu, Yimin ^a   Wang, Haohao ^a   Teng, Lisong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

ceRNA; gastric cancer; H19; HOTAIR; lncRNA

Indexed keywords

FNA1 PROTEIN; GELATINASE A; GELATINASE B; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 675; MYC PROTEIN; PROTEIN; RNA H19; TRANSCRIPTION FACTOR E2F1; TUMOR MARKER; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; APOPTOSIS; BIOINFORMATICS; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME SEGREGATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENHANCER REGION; EPIGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; GENE ONTOLOGY; GENE OVEREXPRESSION; GENE SILENCING; HIGH THROUGHPUT SEQUENCING; HUMAN; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; REVIEW; RNA PROCESSING; RNA SEQUENCE; STOMACH CARCINOMA; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; UPREGULATION; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; STOMACH NEOPLASMS;

BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RNA, LONG NONCODING; STOMACH NEOPLASMS;

EID: 84942288188     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.175     Document Type: Review

References (111)

1. Ferlay J SI, Ervik M, Dikshit R et al. Globocan 2012 v1.0, cancer incidence and mortality worldwide: Iarc cancerbase no. 11. http://globocan.iarc.fr/Default.aspx
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9-29 (2014).
3. Djebali S, Davis CA, Merkel A et al. Landscape of transcription in human cells. Nature 489(7414), 101-108 (2012).
4. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10(3), 155-159 (2009).
5. Novikova IV, Hennelly SP, Tung CS, Sanbonmatsu KY. Rise of the RNA machines: exploring the structure of long non-coding RNAs. J. Mol. Biol. 425(19), 3731-3746 (2013).
6. Pauli A, Rinn JL, Schier AF. Non-coding RNAs as regulators of embryogenesis. Nat. Rev. Genet. 12(2), 136-149 (2011).
7. Lee JT, Bartolomei MS. X-inactivation, imprinting, and long noncoding RNAs in health and disease. Cell 152(6), 1308-1323 (2013).
8. Peschansky VJ, Wahlestedt C. Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics 9(1), 3-12 (2014).
9. Orom UA, Derrien T, Beringer M et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 143(1), 46-58 (2010).
10. Johnsson P, Lipovich L, Grander D, Morris KV. Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim. Biophys. Acta 1840(3), 1063-1071 (2014).
11. Li H, Yu B, Li J et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 5(8), 2318-2329 (2014).
12. Xu TP, Huang MD, Xia R et al. Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression. J. Hematol. Oncol. 7, 63 (2014).
13. Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol. Cell Biol. 34(17), 3182-3193 (2014).
14. GENCODE.www.gencodegenes.org
15. Cao WJ, Wu HL, He BS, Zhang YS, Zhang ZY. Analysis of long non-coding RNA expression profiles in gastric cancer. World J. Gastroenterol. 19(23), 3658-3664 (2013).
16. Lin XC, Zhu Y, Chen WB et al. Integrated analysis of long non-coding RNAs and mRNA expression profiles reveals the potential role of lncRNAs in gastric cancer pathogenesis. Int. J. Oncol. 45(2), 619-628 (2014).
17. Wang Y, Feng X, Jia R et al. Microarray expression profile analysis of long non-coding RNAs of advanced stage human gastric cardia adenocarcinoma. Mol. Genet. Genomics 289(3), 291-302 (2014).
18. Park SM, Park SJ, Kim HJ et al. A known expressed sequence tag, BM742401, is a potent lincRNA inhibiting cancer metastasis. Exp. Mol. Med. 45, e31 (2013).
19. Hu Y, Wang J, Qian J et al. Long non-coding RNA gaplinc regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. Cancer Res. 74(3), 6890-6902 (2014).
20. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 11(4), 254-267 (2011).
21. Reid LH, Davies C, Cooper PR et al. A 1-mb physical map and pac contig of the imprinted domain in 11p15.5 that contains tapa1 and the BWSCR1/WT2 region. Genomics 43(3), 366-375 (1997).
22. Sparago A, Cerrato F, Vernucci M, Ferrero GB, Silengo MC, Riccio A. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat. Genet. 36(9), 958-960 (2004).
23. Lu Y, Lu P, Zhu Z, Xu H, Zhu X. Loss of imprinting of insulin-like growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer. J. Exp. Clin. Cancer Res. 28, 125 (2009).
24. Medrzycki M, Zhang Y, Zhang W et al. Histone H1.3 suppresses H19 noncoding RNA expression and cell growth of ovarian cancer cells. Cancer Res. 74(22), 6463-6473 (2014).
25. Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting e-cadherin expression. Cancer Lett. 333(2), 213-221 (2013).
26. Zhang L, Yang F, Yuan JH et al. Epigenetic activation of the miR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis 34(3), 577-586 (2013).
27. Zhuang M, Gao W, Xu J, Wang P, Shu Y. The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. Biochem. Biophys. Res. Commun. 448(3), 315-322 (2014).
28. Matouk IJ, Mezan S, Mizrahi A et al. The oncofetal H19 RNA connection: Hypoxia, p53 and cancer. Biochim. Biophys. Acta 1803(4), 443-451 (2010).
29. Zhang EB, Han L, Yin DD, Kong R, De W, Chen J. C-myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Med. Oncol. 31(5), 914 (2014).
30. Yang F, Bi J, Xue X et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 279(17), 3159-3165 (2012).
31. Arita T, Ichikawa D, Konishi H et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res. 33(8), 3185-3193 (2013).
32. Gupta RA, Shah N, Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291), 1071-1076 (2010).
33. Zhao W, An Y, Liang Y, Xie XW. Role of HOTAIR long noncoding RNA in metastatic progression of lung cancer. Eur. Rev. Med. Pharmacol. Sci. 18(13), 1930-1936 (2014).
34. Ma MZ, Li CX, Zhang Y et al. Long non-coding RNA HOTAIR, a c-MYC activated driver of malignancy, negatively regulates miRNA-130a in gallbladder cancer. Mol. Cancer 13, 156 (2014).
35. Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J. Int. Med. Res. 39(6), 2119-2128 (2011).
36. Okugawa Y, Toiyama Y, Hur K et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis 35(12), 2731-2739 (2014).
37. Liu XH, Sun M, Nie FQ et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol. Cancer 13, 92 (2014).
38. Endo H, Shiroki T, Nakagawa T et al. Enhanced expression of long non-coding RNA HOTAIR is associated with the development of gastric cancer. PLoS ONE 8(10), e77070 (2013).
39. Hajjari M, Behmanesh M, Sadeghizadeh M, Zeinoddini M. Up-regulation of HOTAIR long non-coding RNA in human gastric adenocarcinoma tissues. Med. Oncol. 30(3), 670 (2013).
40. Zhang EB, Kong R, Yin DD et al. Long noncoding RNA anril indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 5(8), 2276-2292 (2014).
41. Yang F, Xue X, Zheng L et al. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-myc mRNA stability. FEBS J. 281(3), 802-813 (2014).
42. Xu C, Shao Y, Xia T et al. LncRNA-ac130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis. Tumour Biol. 35(10), 9701-9706 (2014).
43. Zhao Y, Guo Q, Chen J, Hu J, Wang S, Sun Y. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol. Rep. 31(1), 358-364 (2014).
44. Wang J, Su L, Chen X et al. MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF. Biomed. Pharmacother. 68(5), 557-564 (2014).
45. Yang F, Xue X, Bi J et al. Long noncoding RNA CCAT1, which could be activated by c-MYC, promotes the progression of gastric carcinoma. J. Cancer Res. Clin. Oncol. 139(3), 437-445 (2013).
46. Lin X, Yang M, Xia T, Guo J. Increased expression of long noncoding RNA ABHD11-AS1 in gastric cancer and its clinical significance. Med. Oncol. 31(7), 42 (2014).
47. Mei D, Song H, Wang K et al. Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. Med. Oncol. 30(4), 709 (2013).
48. Pang Q, Ge J, Shao Y et al. Increased expression of long intergenic non-coding RNA linc00152 in gastric cancer and its clinical significance. Tumour Biol. 35(6), 5441-5447 (2014).
49. Song H, Sun W, Ye G et al. Long non-coding RNA expression profile in human gastric cancer and its clinical significances. J. Transl. Med. 11, 225 (2013).
50. Ding J, Li D, Gong M et al. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. Onco Targets Ther. 7, 1625-1630 (2014).
51. Sun W, Wu Y, Yu X et al. Decreased expression of long noncoding RNA AC096655.1-002 in gastric cancer and its clinical significance. Tumour Biol. 34(5), 2697-2701 (2013).
52. Shao Y, Chen H, Jiang X et al. Low expression of lncRNA-hmlincRNA717 in human gastric cancer and its clinical significances. Tumour Biol. 35(10), 9591-9595 (2014).
53. Sun M, Jin FY, Xia R et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer 14, 319 (2014).
54. Liu Z, Shao Y, Tan L, Shi H, Chen S, Guo J. Clinical significance of the low expression of FER1L4 in gastric cancer patients. Tumour Biol. 35(10), 9613-9617 (2014).
55. Shao Y, Ye M, Jiang X et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. Cancer 120(21), 3320-3328 (2014).
56. Sun M, Xia R, Jin F et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol. 35(2), 1065-1073 (2014).
57. Liu L, Yan B, Yang Z, Zhang X, Gu Q, Yue X. Ncrupar inhibits gastric cancer progression by down-regulating protease-activated receptor-1. Tumour Biol. 35(8), 7821-7829 (2014).
58. Xiao B, Guo J. Long noncoding RNA ac096655.1-002 has been officially named as gastric cancer-associated transcript 1, GACAT1. Tumour Biol. 34(5), 3271 (2013).
59. Chen S, Li P, Xiao B, Guo J. Long noncoding RNA hmlincRNA717 and AC130710 have been officially named as gastric cancer associated transcript 2 (GACAT2) and GACAT3, respectively. Tumour Biol. 35(9), 8351-8352 (2014).
60. Khalil AM, Guttman M, Huarte M et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl Acad. Sci. USA 106(28), 11667-11672 (2009).
61. Grote P, Wittler L, Hendrix D et al. The tissue-specific lncRNA fendrr is an essential regulator of heart and body wall development in the mouse. Dev. Cell. 24(2), 206-214 (2013).
62. Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell 54(6), 787-793 (1988).
63. Pickard MR, Mourtada-Maarabouni M, Williams GT. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim. Biophys. Acta 1832(10), 1613-1623 (2013).
64. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 28(2), 195-208 (2009).
65. Huang CL, Liu D, Nakano J et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin. Cancer Res. 13(23), 6938-6946 (2007).
66. Lee JT. Epigenetic regulation by long noncoding RNAs. Science 338(6113), 1435-1439 (2012).
67. Kotake Y, Nakagawa T, Kitagawa K et al. Long non-coding RNA anril is required for the PRC2 recruitment to and silencing of p15(ink4b) tumor suppressor gene. Oncogene 30(16), 1956-1962 (2011).
68. Piazzi G, Fini L, Selgrad M et al. Epigenetic regulation of delta-like1 controls Notch1 activation in gastric cancer. Oncotarget 2(12), 1291-1301 (2011).
69. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr. Res. 61(5 Pt 2), R24-R29 (2007).
70. Cesana M, Cacchiarelli D, Legnini I et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147(2), 358-369 (2011).
71. Rinn JL, Kertesz M, Wang JK et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129(7), 1311-1323 (2007).
72. Spitale RC, Tsai MC, Chang HY. Rna templating the epigenome: long noncoding RNAs as molecular scaffolds. Epigenetics 6(5), 539-543 (2011).
73. Quinodoz S, Guttman M. Long noncoding RNAs: an emerging link between gene regulation and nuclear organization. Trends Cell Biol. 24(11), 651-663 (2014).
74. Perini G, Diolaiti D, Porro A, Della Valle G. In vivo transcriptional regulation of n-MYC target genes is controlled by e-BOX methylation. Proc. Natl Acad. Sci. USA 102(34), 12117-12122 (2005).
75. Cole MD, Henriksson M. 25 years of the c-MYC oncogene. Semin. Cancer Biol. 16(4), 241 (2006).
76. Calcagno DQ, Leal MF, Demachki S et al. MYC in gastric carcinoma and intestinal metaplasia of young adults. Cancer Genet. Cytogenet. 202(1), 63-66 (2010).
77. Wang KC, Yang YW, Liu B et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472(7341), 120-124 (2011).
78. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim. Biophys. Acta 1815(1), 75-89 (2011).
79. Bulger M, Groudine M. Functional and mechanistic diversity of distal transcription enhancers. Cell 144(3), 327-339 (2011).
80. Phillips-Cremins JE, Sauria ME, Sanyal A et al. Architectural protein subclasses shape 3D organization of genomes during lineage commitment. Cell 153(6), 1281-1295 (2013).
81. Ji P, Diederichs S, Wang W et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22(39), 8031-8041 (2003).
82. BeRNArd D, Prasanth KV, Tripathi V et al. A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J. 29(18), 3082-3093 (2010).
83. Hung T, Chang HY. Long noncoding RNA in genome regulation: prospects and mechanisms. RNA Biol. 7(5), 582-585 (2010).
84. Tauler J, Mulshine JL. Lung cancer and inflammation: interaction of chemokines and HNRNPS. Curr. Opin. Pharmacol. 9(4), 384-388 (2009).
85. Gao WL, Liu M, Yang Y et al. The imprinted H19 gene regulates human placental trophoblast cell proliferation via encoding miR-675 that targets nodal modulator 1 (NOMO1). RNA Biol. 9(7), 1002-1010 (2012).
86. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell 146(3), 353-358 (2011).
87. Sarver AL, Subramanian S. Competing endogenous RNA database. Bioinformation 8(15), 731-733 (2012).
88. Yu G, Yao W, Gumireddy K et al. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear cell renal cell carcinoma progression. Mol. Cancer Ther. 13(12), 3086-3097 (2014).
89. Xia T, Liao Q, Jiang X et al. Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci. Rep. 4, 6088 (2014).
90. Xiao B, Guo J, Miao Y et al. Detection of miR-106a in gastric carcinoma and its clinical significance. Clin. Chim. Acta 400(1-2), 97-102 (2009).
91. Kameda T, Yasui W, Yoshida K et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res. 50(24), 8002-8009 (1990).
92. Lemoine NR, Jain S, Silvestre F et al. Amplification and overexpression of the egf receptor and c-ERBB-2 proto-oncogenes in human stomach cancer. Br. J. Cancer 64(1), 79-83 (1991).
93. Bosson AD, Zamudio JR, Sharp PA. Endogenous miRNA and target concentrations determine susceptibility to potential ceRNA competition. Mol. Cell 56(3), 347-359 (2014).
94. Denzler R, Agarwal V, Stefano J, Bartel DP, Stoffel M. Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol. Cell 54(5), 766-776 (2014).
95. Jens M, Rajewsky N. Competition between target sites of regulators shapes post-transcriptional gene regulation. Nat. Rev. Genet. 16(2), 113-126 (2015).
96. Kam Y, Rubinstein A, Naik S et al. Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using fit-PNA molecular beacons. Cancer Lett. 352(1), 90-96 (2014).
97. Huang JL, Zheng L, Hu YW, Wang Q. Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis 35(3), 507-514 (2014).
98. Derrien T, Johnson R, Bussotti G et al. The gencode v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 22(9), 1775-1789 (2012).
99. Huang X, Yuan T, Tschannen M et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics 14, 319 (2013).
100. Lee GL, Dobi A, Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test. Nat. Rev. Urol. 8(3), 123-124 (2011).
101. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202-209 (2014).
102. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011).
103. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407), 330-337 (2012).
104. Akrami R, Jacobsen A, Hoell J, Schultz N, Sander C, Larsson E. Comprehensive analysis of long non-coding RNAs in ovarian cancer reveals global patterns and targeted DNA amplification. PLoS ONE 8(11), e80306 (2013).
105. Zhang XQ, Sun S, Lam KF et al. A long non-coding RNA signature in glioblastoma multiforme predicts survival. Neurobiol. Dis. 58, 123-131 (2013).
106. Bhartiya D, Pal K, Ghosh S et al. lncRNome: a comprehensive knowledgebase of human long noncoding RNAs. Database (Oxford) 2013, bat034 (2013).
107. Chen G, Wang Z, Wang D et al. LncRNAdisease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 41, D983-D986 (2013).
108. Paraskevopoulou MD, Georgakilas G, Kostoulas N et al. Diana-lncbase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res. 41, D239-D245 (2013).
109. Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291), 1067-1070 (2010).
110. Meade BR, Gogoi K, Hamil AS et al. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat. Biotechnol. 32(12), 1256-1261 (2014).
111. Cheng CJ, Bahal R, Babar IA et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518(7537), 107-110 (2015).